Key Dates and Disclosure Events Shareholders Need to Know. The lawsuit claims Anavex called its controls effective for months before a for-cause CEO termination, a late filing, and amended reports allegedly exposed a material weakness.
NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Anavex Life Sciences Corp. (NASDAQ: AVXL) to contact the firm about a pending securities class action. WHO IS AFFECTED: Those who purchased Anavex securities between November 26, 2025 and August 28, 2026 may be entitled to recover damages. See if you could be eligible to recover or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
May 6, 2026: AVXL slips 0.59%; May 12, 2026: shares fall 5.55%; August 31, 2026: shares slide another 6.35%. Investors have until November 30, 2026 to seek lead plaintiff status.
The Anavex Timeline: Disclosure Events That Escalated
The story opens with reassurance. As set forth in the complaint, the November 25, 2025 annual report and the February 9, 2026 quarterly report each described Anavex's disclosure controls as effective and carried a Sarbanes-Oxley certification. The action contends that, behind those certifications, clinical and regulatory information ran through a single executive who kept it from the Board.
Then the warning signs multiplied. A special committee of independent directors terminated the chief executive for Cause on April 30, 2026, which the Company disclosed on May 6 in a press release the complaint says downplayed the exit by describing a "departure." Five days later, a Form 12b-25 stated the quarterly report could not be filed on time while the committee's review continued.
Timeline of Alleged Disclosure Failures
- November 25, 2025: Controls reported effective as of September 30, 2025; it is alleged the accompanying SOX certification was false.
- February 9, 2026: Disclosure controls reported effective as of December 31, 2025.
- May 11, 2026: Late-filing notice links the delayed quarterly report to the special committee's review.
- August 26 and 28, 2026: Amended reports state controls were not effective as of September 30, 2025 and December 31, 2025.
- August 28, 2026: New quarterly reports extend that finding through June 30, 2026 and disclose that development of ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066 was paused.
What the August 28 Filings Allegedly Corrected
In its amended annual report, the Company stated that its former CEO "failed to set an appropriate tone at the top" and "took steps to disincentivize" regulatory and clinical compliance. The lawsuit alleges these disclosures corrected prior alleged misstatements about control effectiveness, closing a roughly nine-month gap between certification and correction.
"Timely disclosure of material developments is fundamental to fair and efficient markets. The complaint alleges that Anavex described its controls as effective in two periodic reports before acknowledging, in August 2026, a material weakness dating back to September 30, 2025. Shareholders who bought during that window should understand how each step in that sequence may affect their rights," said Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP.
Calculate your potential recovery or call (212) 363-7500.
Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the AVXL Lawsuit
Q: What specific misstatements does the AVXL lawsuit allege? A: The complaint alleges that Anavex made materially false or misleading statements during the Class Period about the effectiveness of its internal control over financial reporting, its disclosure controls, and its regulatory risks. According to the complaint, these statements omitted alleged misconduct by its former CEO.
Q: When did Anavex Life Sciences Corp. allegedly mislead investors? A: The Class Period runs from November 26, 2025 to August 28, 2026. The complaint alleges that corrective disclosures revealed information that caused multiple successive stock declines on May 6, May 12, and August 31, 2026.
Q: What court was the AVXL class action filed in? A: The case was filed in the United States District Court for the Southern District of New York, governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.
Q: What if I already sold my AVXL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
Tel: (212) 363-7500\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-anavex-life-sciences-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-november-30-2026---avxl-302900738.html
SOURCE Levi & Korsinsky, LLP
